FDA Expands Indication for Use of Abemaciclib With Early, High-Risk Breast Cancer

FRIDAY, March 10, 2023 (HealthDay News) -- Abemaciclib (Verzenio) with endocrine therapy (tamoxifen or an aromatase inhibitor) is now approved for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at high risk for recurrence, the U.S. Food and Drug Administration announced on March 3.
This priority approval expands the indication by removing the Ki-67 testing requirement to identify high-risk patients (defined as having either at least four pathologic axillary lymph nodes or one to three pathologic axillary lymph nodes and either tumor grade 3 or a tumor size ≥50 mm).
This approval was based on a randomized trial of two years of abemaciclib plus physician’s choice of standard endocrine therapy (tamoxifen or an aromatase inhibitor) or standard endocrine therapy alone. The study showed a statistically significant difference in the intent-to-treat population for invasive disease-free survival (hazard ratio, 0.653). At 48 months, invasive disease-free survival was 85.5 percent for abemaciclib plus standard endocrine therapy and 78.6 percent for standard endocrine therapy alone.
Diarrhea, infections, neutropenia, fatigue, leukopenia, nausea, anemia, and headache were the most common adverse reactions (≥20 percent).
The expanded approval of abemaciclib was granted to Eli Lilly.
Related Posts
China to Drop COVID Test Requirement for Foreign Travelers
MONDAY, Aug. 28, 2023 (HealthDay News) -- Starting Wed., Aug. 30, travelers to...
Se propagan los casos de unas peligrosas infecciones fúngicas resistentes a los medicamentos
MARTES, 21 de marzo de 2023 (HealthDay News) -- La popular serie de HBO, "The...
Acute Pancreatitis May Progress to Chronic With Sustained Heavy Alcohol Use
WEDNESDAY, Sept. 20, 2023 (HealthDay News) -- Many patients with recurrent acute...
Men Offered Surgery More Often Than Women When Carpal Tunnel Strikes
THURSDAY, March 24, 2022 (HealthDay News) -- Men are more likely than women to...